Regulation of endothelial cell functions by basement membrane‐ and arachidonic acid‐derived products

Angiogenesis, the formation of new blood vessels from preexisting vasculature, is required for normal physiological as well as pathological events. The angiogenic process requires endothelial cells to proliferate, migrate, and undergo tubulogenesis. These multistep processes necessitate secretion of pro‐angiogenic growth factors, activation of specific intracellular signaling, and interaction of endothelial cells with basement membrane (BM) extracellular matrix components. The generation and release of angiogenic molecules are highly regulated and are influenced by numerous factors, including BM‐derived fragments, proteolytic enzymes, as well as metabolites of arachidonic acid (AA). The interactions between these key modulators of angiogenesis is extremely complex, as AA metabolites can regulate the synthesis of soluble angiogenic factors, BM components, as well as enzymes capable of cleaving BM components, which result in the generation of pro‐ and/or anti‐angiogenic products. Furthermore, some BM‐derived fragments can alter the expression of AA‐converting enzymes and consequently the synthesis of angiogenic factors. In this review we describe the relationship between BM components and AA metabolites with respect to the regulation of endothelial cell functions in health and disease. Copyright © 2009 John Wiley & Sons, Inc.

[1]  V. Keshamouni,et al.  Human α1 type IV collagen NC1 domain exhibits distinct antiangiogenic activity mediated by α1β1 integrin. , 2020, The Journal of clinical investigation.

[2]  A. Pshezhetsky,et al.  Caspase-3 Activation Triggers Extracellular Cathepsin L Release and Endorepellin Proteolysis* , 2008, Journal of Biological Chemistry.

[3]  E. Crivellato,et al.  Mast cells and tumour angiogenesis: new insight from experimental carcinogenesis. , 2008, Cancer letters.

[4]  J. Redondo,et al.  PGE2 induces angiogenesis via MT1-MMP-mediated activation of the TGFbeta/Alk5 signaling pathway. , 2008, Blood.

[5]  A. Pozzi,et al.  PPARα Ligands as Antitumorigenic and Antiangiogenic Agents , 2008, PPAR research.

[6]  N. Ferrara,et al.  Role of myeloid cells in tumor angiogenesis and growth. , 2008, Trends in cell biology.

[7]  Baolin Zhang,et al.  An essential role for SRC-activated STAT-3 in 14,15-EET-induced VEGF expression and angiogenesis. , 2008, Blood.

[8]  C. Boosani,et al.  RETRACTED ARTICLE: Inhibition of Tumor Angiogenesis by Tumstatin: Insights into Signaling Mechanisms and Implications in Cancer Regression , 2008, Pharmaceutical Research.

[9]  Mahavir Singh,et al.  Cytochrome P450 (CYP) 2J2 gene transfection attenuates MMP‐9 via inhibition of NF‐κβ in hyperhomocysteinemia , 2008, Journal of cellular physiology.

[10]  B. Hudson,et al.  Mammalian collagen IV , 2008, Microscopy research and technique.

[11]  J. Miner Laminins and their roles in mammals , 2008, Microscopy research and technique.

[12]  R. Iozzo,et al.  Novel interactions of perlecan: Unraveling perlecan's role in angiogenesis , 2008, Microscopy research and technique.

[13]  N. Smyth,et al.  Nidogens—Extracellular matrix linker molecules , 2008, Microscopy research and technique.

[14]  L. Coussens,et al.  Polarized immune responses differentially regulate cancer development , 2008, Immunological reviews.

[15]  X. Xie,et al.  Celecoxib inhibits tumor growth and angiogenesis in an orthotopic implantation tumor model of human colon cancer. , 2008, Experimental oncology.

[16]  D. Mukherjee Nonsteroidal anti-inflammatory drugs and the heart: what is the danger? , 2008, Congestive heart failure.

[17]  M. Koch,et al.  Tumor Escape from Endogenous, Extracellular Matrix–Associated Angiogenesis Inhibitors by Up-Regulation of Multiple Proangiogenic Factors , 2008, Clinical Cancer Research.

[18]  J. Folkman,et al.  Angiogenesis is regulated by a novel mechanism: pro- and antiangiogenic proteins are organized into separate platelet alpha granules and differentially released. , 2008, Blood.

[19]  S. Ylä-Herttuala,et al.  15-Lipoxygenase-1 Prevents Vascular Endothelial Growth Factor A– and Placental Growth Factor–Induced Angiogenic Effects in Rabbit Skeletal Muscles via Reduction in Growth Factor mRNA Levels, NO Bioactivity, and Downregulation of VEGF Receptor 2 Expression , 2008, Circulation research.

[20]  A. Pozzi,et al.  Integrin α2β1 Is the Required Receptor for Endorepellin Angiostatic Activity* , 2008, Journal of Biological Chemistry.

[21]  S. Donnini,et al.  Prostaglandin E2 Regulates Angiogenesis via Activation of Fibroblast Growth Factor Receptor-1* , 2008, Journal of Biological Chemistry.

[22]  Sui Huang,et al.  PPARα agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition , 2008, Proceedings of the National Academy of Sciences.

[23]  I. Fleming Vascular cytochrome p450 enzymes: physiology and pathophysiology. , 2008, Trends in cardiovascular medicine.

[24]  A. Pozzi,et al.  Integrin alpha2beta1 is the required receptor for endorepellin angiostatic activity. , 2008, The Journal of biological chemistry.

[25]  D. Ganea,et al.  PGE2-induced metalloproteinase-9 is essential for dendritic cell migration. , 2008, Blood.

[26]  D. Noonan,et al.  Inflammation, inflammatory cells and angiogenesis: decisions and indecisions , 2008, Cancer and Metastasis Reviews.

[27]  R. Kalluri,et al.  Type IV collagen α6 chain‐derived noncollagenous domain 1 (α6(IV)NC1) inhibits angiogenesis and tumor growth , 2007 .

[28]  P Reddanna,et al.  Computer aided drug design approaches to develop cyclooxygenase based novel anti-inflammatory and anti-cancer drugs. , 2007, Current pharmaceutical design.

[29]  W. Glasgow,et al.  15(S)-HETE production in human retinal microvascular endothelial cells by hypoxia: Novel role for MEK1 in 15(S)-HETE induced angiogenesis. , 2007, Investigative ophthalmology & visual science.

[30]  Sriram Krishnamoorthy,et al.  Lipoxygenase metabolism: roles in tumor progression and survival , 2007, Cancer and Metastasis Reviews.

[31]  Raghu Kalluri,et al.  Structure and Function of Basement Membranes , 2007, Experimental biology and medicine.

[32]  V. Holla,et al.  Targeting cyclooxygenase-2 and the epidermal growth factor receptor for the prevention and treatment of intestinal cancer. , 2007, Cancer research.

[33]  Hyunsook Kim,et al.  Cyclooxygenase-2 promotes cell proliferation, migration and invasion in U2OS human osteosarcoma cells , 2007, Experimental & Molecular Medicine.

[34]  V. Keshamouni,et al.  Regulation of COX-2 mediated signaling by alpha3 type IV noncollagenous domain in tumor angiogenesis. , 2007, Blood.

[35]  A. Pozzi,et al.  Peroxisomal Proliferator-activated Receptor-α-dependent Inhibition of Endothelial Cell Proliferation and Tumorigenesis* , 2007, Journal of Biological Chemistry.

[36]  A. Pozzi,et al.  Prostaglandin E2-EP4 Receptor Promotes Endothelial Cell Migration via ERK Activation and Angiogenesis in Vivo* , 2007, Journal of Biological Chemistry.

[37]  Baolin Zhang,et al.  15(S)-hydroxyeicosatetraenoic acid-induced angiogenesis requires STAT3-dependent expression of VEGF. , 2007, Cancer research.

[38]  S. Narumiya,et al.  Prostaglandin E Receptors* , 2007, Journal of Biological Chemistry.

[39]  L. Coussens,et al.  Humoral immunity, inflammation and cancer. , 2007, Current opinion in immunology.

[40]  J. Falck,et al.  Activation of Vascular Endothelial Growth Factor through Reactive Oxygen Species Mediates 20-Hydroxyeicosatetraenoic Acid-Induced Endothelial Cell Proliferation , 2007, Journal of Pharmacology and Experimental Therapeutics.

[41]  Sui Huang,et al.  PPARα Deficiency in Inflammatory Cells Suppresses Tumor Growth , 2007, PloS one.

[42]  D. Aronoff,et al.  Prostaglandin E(2) inhibits collagen expression and proliferation in patient-derived normal lung fibroblasts via E prostanoid 2 receptor and cAMP signaling. , 2007, American journal of physiology. Lung cellular and molecular physiology.

[43]  Raymond N DuBois,et al.  NSAIDs and cancer prevention: targets downstream of COX-2. , 2007, Annual review of medicine.

[44]  I. Fleming Epoxyeicosatrienoic acids, cell signaling and angiogenesis. , 2007, Prostaglandins & other lipid mediators.

[45]  Huanchen Sha,et al.  Optimizing drug delivery for enhancing therapeutic efficacy of recombinant human endostatin in cancer treatment. , 2007, Critical reviews in therapeutic drug carrier systems.

[46]  Sui Huang,et al.  PPAR\(\alpha\) Deficiency in Inflammatory Cells Suppresses Tumor Growth , 2007 .

[47]  S. Baker,et al.  The PTEN/Akt pathway dictates the direct alphaVbeta3-dependent growth-inhibitory action of an active fragment of tumstatin in glioma cells in vitro and in vivo. , 2006, Cancer research.

[48]  D. Nebert,et al.  The role of cytochrome P450 enzymes in endogenous signalling pathways and environmental carcinogenesis , 2006, Nature Reviews Cancer.

[49]  A. Griffioen,et al.  Monocyte/macrophage infiltration in tumors: modulators of angiogenesis , 2006, Journal of leukocyte biology.

[50]  K. Camphausen,et al.  Endorepellin in vivo: targeting the tumor vasculature and retarding cancer growth and metabolism. , 2006, Journal of the National Cancer Institute.

[51]  A. Pozzi,et al.  EP2, a receptor for PGE2, regulates tumor angiogenesis through direct effects on endothelial cell motility and survival , 2006, Oncogene.

[52]  Y. Shiratori,et al.  Tumor‐specific expression of the RGD‐α3(IV)NC1 domain suppresses endothelial tube formation and tumor growth in mice , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[53]  I. Fleming,et al.  From endothelium-derived hyperpolarizing factor (EDHF) to angiogenesis: Epoxyeicosatrienoic acids (EETs) and cell signaling. , 2006, Pharmacology & therapeutics.

[54]  A. Pozzi,et al.  Integrin α3β1, a Novel Receptor for α3(IV) Noncollagenous Domain and a Trans-dominant Inhibitor for Integrin αvβ3* , 2006, Journal of Biological Chemistry.

[55]  D. Nie,et al.  Mechanisms Regulating Tumor Angiogenesis by 12-Lipoxygenase in Prostate Cancer Cells* , 2006, Journal of Biological Chemistry.

[56]  R. Kalluri,et al.  Cathepsin S Controls Angiogenesis and Tumor Growth via Matrix-derived Angiogenic Factors* , 2006, Journal of Biological Chemistry.

[57]  G. Alghisi,et al.  Vascular integrins in tumor angiogenesis: mediators and therapeutic targets. , 2006, Endothelium : journal of endothelial cell research.

[58]  A. Dannenberg,et al.  Targeting Prostaglandin E2 Receptors as an Alternative Strategy to Block Cyclooxygenase-2-dependent Extracellular Matrix-induced Matrix Metalloproteinase-9 Expression by Macrophages* , 2006, Journal of Biological Chemistry.

[59]  Baolin Zhang,et al.  Fibroblast Growth Factor-2 Is a Downstream Mediator of Phosphatidylinositol 3-Kinase-Akt Signaling in 14,15-Epoxyeicosatrienoic Acid-induced Angiogenesis* , 2006, Journal of Biological Chemistry.

[60]  A. Pozzi,et al.  Integrin alpha3beta1, a novel receptor for alpha3(IV) noncollagenous domain and a trans-dominant Inhibitor for integrin alphavbeta3. , 2006, The Journal of biological chemistry.

[61]  K. Lundholm,et al.  Cyclooxygenase inhibition in early onset of tumor growth and related angiogenesis evaluated in EP1 and EP3 knockout tumor-bearing mice , 2006, Angiogenesis.

[62]  K. Ha,et al.  Prostaglandin E2 stimulates angiogenesis by activating the nitric oxide/cGMP pathway in human umbilical vein endothelial cells , 2005, Experimental & Molecular Medicine.

[63]  F Peter Guengerich,et al.  Function of human cytochrome P450s: characterization of the orphans. , 2005, Biochemical and biophysical research communications.

[64]  R. Busse,et al.  Cytochrome P450 epoxygenases 2C8 and 2C9 are implicated in hypoxia-induced endothelial cell migration and angiogenesis , 2005, Journal of Cell Science.

[65]  I. Barshack,et al.  Inhibition of carcinogenesis in transgenic mouse models over-expressing 15-lipoxygenase in the vascular wall under the control of murine preproendothelin-1 promoter. , 2005, Cancer letters.

[66]  S. Fischer,et al.  Lack of expression of the EP2 but not EP3 receptor for prostaglandin E2 results in suppression of skin tumor development. , 2005, Cancer research.

[67]  Baolin Zhang,et al.  15(S)-hydroxyeicosatetraenoic acid induces angiogenesis via activation of PI3K-Akt-mTOR-S6K1 signaling. , 2005, Cancer research.

[68]  A. Pozzi,et al.  Characterization of 5,6- and 8,9-Epoxyeicosatrienoic Acids (5,6- and 8,9-EET) as Potent in Vivo Angiogenic Lipids* , 2005, Journal of Biological Chemistry.

[69]  T. Salo,et al.  Generation of biologically active endostatin fragments from human collagen XVIII by distinct matrix metalloproteases. , 2005, Experimental cell research.

[70]  P. Opolon,et al.  Canstatin Acts on Endothelial and Tumor Cells via Mitochondrial Damage Initiated through Interaction with αvβ3 and αvβ5 Integrins , 2005 .

[71]  R. Iozzo,et al.  BMP-1/Tolloid-like Metalloproteases Process Endorepellin, the Angiostatic C-terminal Fragment of Perlecan* , 2005, Journal of Biological Chemistry.

[72]  J. Falck,et al.  Inhibitors of cytochrome P450 4A suppress angiogenic responses. , 2005, The American journal of pathology.

[73]  S. Taniura,et al.  The cyclooxygenase inhibitor indomethacin modulates gene expression and represses the extracellular matrix protein laminin gamma1 in human glioblastoma cells. , 2005, Experimental cell research.

[74]  R. Busse,et al.  Cytochrome P4502C9-Derived Epoxyeicosatrienoic Acids Induce the Expression of Cyclooxygenase-2 in Endothelial Cells , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[75]  V. Keshamouni,et al.  Human alpha1 type IV collagen NC1 domain exhibits distinct antiangiogenic activity mediated by alpha1beta1 integrin. , 2005, The Journal of clinical investigation.

[76]  P. Opolon,et al.  Canstatin acts on endothelial and tumor cells via mitochondrial damage initiated through interaction with alphavbeta3 and alphavbeta5 integrins. , 2005, Cancer research.

[77]  FDA warning on NSAID use. , 2005, FDA consumer.

[78]  R. Breyer,et al.  Generation of a conditional allele of the mouse prostaglandin EP4 receptor , 2004, Genesis.

[79]  J. Morrow,et al.  Colon Carcinoma Cell Growth Is Associated with Prostaglandin E2/EP4 Receptor-evoked ERK Activation* , 2004, Journal of Biological Chemistry.

[80]  Samuel A. Santoro,et al.  Endorepellin causes endothelial cell disassembly of actin cytoskeleton and focal adhesions through α2β1 integrin , 2004, The Journal of cell biology.

[81]  C. Witton,et al.  Cyclooxygenase 2 (COX2) expression is associated with poor outcome in ER‐negative, but not ER‐positive, breast cancer , 2004, Histopathology.

[82]  Tianyuan Zhang,et al.  The C-terminal domain of canstatin suppresses in vivo tumor growth associated with proliferation of endothelial cells. , 2004, Biochemical and biophysical research communications.

[83]  L. Claesson‐Welsh,et al.  Laminin-1 Promotes Angiogenesis in Synergy with Fibroblast Growth Factor by Distinct Regulation of the Gene and Protein Expression Profile in Endothelial Cells* , 2004, Journal of Biological Chemistry.

[84]  L. R. Howe,et al.  Extracellular Matrix-induced Cyclooxygenase-2 Regulates Macrophage Proteinase Expression* , 2004, Journal of Biological Chemistry.

[85]  K. Alitalo,et al.  An Endostatin-derived Peptide Interacts with Integrins and Regulates Actin Cytoskeleton and Migration of Endothelial Cells* , 2004, Journal of Biological Chemistry.

[86]  S. Gately,et al.  Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy. , 2004, Seminars in oncology.

[87]  N. Chandel,et al.  The α4 laminin subunit regulates endothelial cell survival , 2004 .

[88]  B. Hudson,et al.  αvβ3 and αvβ5 Integrins Bind Both the Proximal RGD Site and Non-RGD Motifs within Noncollagenous (NC1) Domain of the α3 Chain of Type IV Collagen , 2004, Journal of Biological Chemistry.

[89]  A. Imberty,et al.  Characterization of Endostatin Binding to Heparin and Heparan Sulfate by Surface Plasmon Resonance and Molecular Modeling , 2004, Journal of Biological Chemistry.

[90]  Xiang Fang,et al.  Epoxyeicosatrienoic acids (EETs): metabolism and biochemical function. , 2004, Progress in lipid research.

[91]  J. C. Jones,et al.  The alpha4 laminin subunit regulates endothelial cell survival. , 2004, Experimental cell research.

[92]  B. Hudson,et al.  Alpha(v)beta3 and alpha(v)beta5 integrins bind both the proximal RGD site and non-RGD motifs within noncollagenous (NC1) domain of the alpha3 chain of type IV collagen: implication for the mechanism of endothelia cell adhesion. , 2004, The Journal of biological chemistry.

[93]  S. Gately The Contributions of Cyclooxygenase-2 to Tumor Angiogenesis , 2004, Cancer and Metastasis Reviews.

[94]  Tianyuan Zhang,et al.  Canstatin-N fragment inhibits in vitro endothelial cell proliferation and suppresses in vivo tumor growth. , 2003, Biochemical and biophysical research communications.

[95]  J. Regan EP2 and EP4 prostanoid receptor signaling. , 2003, Life sciences.

[96]  S. Adler,et al.  Role of 12-lipoxygenase in the stimulation of p38 mitogen-activated protein kinase and collagen alpha5(IV) in experimental diabetic nephropathy and in glucose-stimulated podocytes. , 2003, Journal of the American Society of Nephrology : JASN.

[97]  S. Donnini,et al.  Angiosuppressive and angiostimulatory effects exerted by synthetic partial sequences of endostatin. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[98]  N. Kalia,et al.  Effects of aspirin and indomethacin on endothelial cell proliferation in vitro , 2003, Journal of gastroenterology and hepatology.

[99]  R. Mansel,et al.  Levels of expression of lipoxygenases and cyclooxygenase-2 in human breast cancer. , 2003, Prostaglandins, leukotrienes, and essential fatty acids.

[100]  T. Veenstra,et al.  Anti-angiogenic activity of human endostatin is HIF-1-independent in vitro and sensitive to timing of treatment in a human saphenous vein assay. , 2003, Molecular cancer therapeutics.

[101]  H. Reber,et al.  PGE(2) is generated by specific COX-2 activity and increases VEGF production in COX-2-expressing human pancreatic cancer cells. , 2003, Biochemical and biophysical research communications.

[102]  K. Tryggvason,et al.  Alport's syndrome, Goodpasture's syndrome, and type IV collagen. , 2003, The New England journal of medicine.

[103]  R. Hynes,et al.  Physiological levels of tumstatin, a fragment of collagen IV alpha3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via alphaV beta3 integrin. , 2003, Cancer cell.

[104]  Raghu Kalluri,et al.  Human tumstatin and human endostatin exhibit distinct antiangiogenic activities mediated by αvβ3 and α5β1 integrins , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[105]  J. Regan,et al.  Prostaglandin E2 Induced Functional Expression of Early Growth Response Factor-1 by EP4, but Not EP2, Prostanoid Receptors via the Phosphatidylinositol 3-Kinase and Extracellular Signal-regulated Kinases* , 2003, The Journal of Biological Chemistry.

[106]  R. Busse,et al.  Cytochrome P450 2C9‐derived epoxyeicosatrienoic acids induce angiogenesis via cross‐talk with the epidermal growth factor receptor , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[107]  P. Opolon,et al.  Fenofibrate inhibits angiogenesis in vitro and in vivo , 2003, Cellular and Molecular Life Sciences CMLS.

[108]  Raymond N DuBois,et al.  Cyclooxygenase-1 is overexpressed and promotes angiogenic growth factor production in ovarian cancer. , 2003, Cancer research.

[109]  M. Cross,et al.  Angiostatin and endostatin inhibit endothelial cell migration in response to FGF and VEGF without interfering with specific intracellular signal transduction pathways , 2003, FEBS letters.

[110]  Shawn M. Sweeney,et al.  Endorepellin, a Novel Inhibitor of Angiogenesis Derived from the C Terminus of Perlecan* , 2003, The Journal of Biological Chemistry.

[111]  Yukihiko Sugimoto,et al.  Host Prostaglandin E2-EP3 Signaling Regulates Tumor-Associated Angiogenesis and Tumor Growth , 2003, The Journal of experimental medicine.

[112]  Ko-Hua Chen,et al.  Transforming growth factor-ß2 inhibition of corneal endothelial proliferation mediated by prostaglandin , 2003, Current eye research.

[113]  R. Hynes,et al.  Physiological levels of tumstatin, a fragment of collagen IV alpha3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via alphaV beta3 integrin. , 2003, Cancer cell.

[114]  R. Kalluri,et al.  Human tumstatin and human endostatin exhibit distinct antiangiogenic activities mediated by alpha v beta 3 and alpha 5 beta 1 integrins. , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[115]  H. Reber,et al.  PGE(2) is generated by specific COX-2 activity and increases VEGF production in COX-2-expressing human pancreatic cancer cells. , 2003, Biochemical and biophysical research communications.

[116]  R. Busse,et al.  Epoxygenase-driven angiogenesis in human lung microvascular endothelial cells. , 2003, American journal of physiology. Heart and circulatory physiology.

[117]  Yukihiko Sugimoto,et al.  Host Prostaglandin E 2-EP 3 Signaling Regulates Tumor-Associated Angiogenesis and Tumor Growth , 2003 .

[118]  R. Timpl,et al.  Role of heparan sulfate domain organization in endostatin inhibition of endothelial cell function , 2002, The EMBO journal.

[119]  K. Alitalo,et al.  Endostatin associates with integrin alpha5beta1 and caveolin-1, and activates Src via a tyrosyl phosphatase-dependent pathway in human endothelial cells. , 2002, Cancer research.

[120]  J. Wallace,et al.  Divergent effects of new cyclooxygenase inhibitors on gastric ulcer healing: Shifting the angiogenic balance , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[121]  T. Adrian,et al.  Lipoxygenase inhibitors attenuate growth of human pancreatic cancer xenografts and induce apoptosis through the mitochondrial pathway. , 2002, Molecular cancer therapeutics.

[122]  J. Falck,et al.  Biochemical and molecular properties of the cytochrome P450 arachidonic acid monooxygenases. , 2002, Prostaglandins & other lipid mediators.

[123]  E. Fleck,et al.  PPAR activators inhibit endothelial cell migration by targeting Akt. , 2002, Biochemical and biophysical research communications.

[124]  Young-Guen Kwon,et al.  Endostatin binds to the catalytic domain of matrix metalloproteinase‐2 , 2002, FEBS letters.

[125]  R. Timpl,et al.  Expression and distribution of laminin alpha1 and alpha2 chains in embryonic and adult mouse tissues: an immunochemical approach. , 2002, Experimental cell research.

[126]  D. Nie,et al.  Cyclooxygenase, lipoxygenase and tumor angiogenesis , 2002, Cellular and Molecular Life Sciences CMLS.

[127]  Jian-Kang Chen,et al.  Heparin-binding EGF-like growth factor mediates the biological effects of P450 arachidonate epoxygenase metabolites in epithelial cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[128]  H. Kleinman,et al.  Laminin γ1 chain peptide, C-16 (KAFDITYVRLKF), promotes migration, MMP-9 secretion, and pulmonary metastasis of B16–F10 mouse melanoma cells , 2002, British Journal of Cancer.

[129]  J. Engel,et al.  Domain structure and organisation in extracellular matrix proteins. , 2002, Matrix biology : journal of the International Society for Matrix Biology.

[130]  C. Kahn,et al.  Tumstatin, an Endothelial Cell-Specific Inhibitor of Protein Synthesis , 2002, Science.

[131]  Rajnish A. Gupta,et al.  Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2 , 2001, Nature Reviews Cancer.

[132]  S. Jain,et al.  Matrilysin cleavage of corneal collagen type XVIII NC1 domain and generation of a 28-kDa fragment. , 2001, Investigative ophthalmology & visual science.

[133]  R. Kalluri,et al.  Extracellular Matrix-derived Peptide Binds to αvβ3 Integrin and Inhibits Angiogenesis* , 2001, The Journal of Biological Chemistry.

[134]  R. Iozzo,et al.  Heparan sulfate proteoglycans: intricate molecules with intriguing functions. , 2001, The Journal of clinical investigation.

[135]  H. Kleinman,et al.  An angiogenic laminin site and its antagonist bind through the αvβ3 and α5β1 integrins , 2001 .

[136]  G. Lip,et al.  Plasma vascular endothelial growth factor and its receptor Flt-1 in patients with hyperlipidemia and atherosclerosis and the effects of fluvastatin or fenofibrate. , 2001, The American journal of cardiology.

[137]  R. Kalluri,et al.  Identification of the Anti-angiogenic Site within Vascular Basement Membrane-derived Tumstatin* , 2001, The Journal of Biological Chemistry.

[138]  D. Mukhopadhyay,et al.  Cell surface glypicans are low-affinity endostatin receptors. , 2001, Molecular cell.

[139]  T. Veikkola,et al.  Interaction of endostatin with integrins implicated in angiogenesis. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[140]  R. Busse,et al.  Endothelium-Derived Hyperpolarizing Factor Synthase (Cytochrome P450 2C9) Is a Functionally Significant Source of Reactive Oxygen Species in Coronary Arteries , 2001, Circulation research.

[141]  R. Kalluri,et al.  Extracellular matrix-derived peptide binds to alpha(v)beta(3) integrin and inhibits angiogenesis. , 2001, The Journal of biological chemistry.

[142]  H. Kleinman,et al.  An angiogenic laminin site and its antagonist bind through the alpha(v)beta3 and alpha5beta1 integrins. , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[143]  R. Breyer,et al.  Prostanoid receptors: subtypes and signaling. , 2001, Annual review of pharmacology and toxicology.

[144]  U. Felbor,et al.  Generation and degradation of human endostatin proteins by various proteinases , 2000, FEBS letters.

[145]  K. W. Kim,et al.  Endostatin inhibits endothelial and tumor cellular invasion by blocking the activation and catalytic activity of matrix metalloproteinase. , 2000, Cancer research.

[146]  T. Sasaki,et al.  Endostatins derived from collagens XV and XVIII differ in structural and binding properties, tissue distribution and anti-angiogenic activity. , 2000, Journal of molecular biology.

[147]  R. Kalluri,et al.  Two RGD-independent αvβ3 Integrin Binding Sites on Tumstatin Regulate Distinct Anti-tumor Properties* , 2000, The Journal of Biological Chemistry.

[148]  P. Yurchenco,et al.  Form and function: The laminin family of heterotrimers , 2000, Developmental dynamics : an official publication of the American Association of Anatomists.

[149]  J. Monboisse,et al.  A peptide of the alpha 3(IV) chain of type IV collagen modulates stimulated neutrophil function via activation of cAMP-dependent protein kinase and Ser/Thr protein phosphatase. , 2000, Cellular signalling.

[150]  D. Nie,et al.  Eicosanoid regulation of angiogenesis: role of endothelial arachidonate 12-lipoxygenase. , 2000, Blood.

[151]  D. Harder,et al.  Cerebral microvascular endothelial cell tube formation: role of astrocytic epoxyeicosatrienoic acid release. , 2000, American journal of physiology. Heart and circulatory physiology.

[152]  Peter C. Brooks,et al.  New Functions for Non-collagenous Domains of Human Collagen Type IV , 2000, The Journal of Biological Chemistry.

[153]  H. Ploegh,et al.  Secreted cathepsin L generates endostatin from collagen XVIII , 2000, The EMBO journal.

[154]  R. Kalluri,et al.  Canstatin, a Novel Matrix-derived Inhibitor of Angiogenesis and Tumor Growth* , 2000, The Journal of Biological Chemistry.

[155]  R. Kalluri,et al.  Two RGD-independent alpha vbeta 3 integrin binding sites on tumstatin regulate distinct anti-tumor properties. , 2000, The Journal of biological chemistry.

[156]  J. Folkman,et al.  The generation of endostatin is mediated by elastase. , 1999, Cancer research.

[157]  J. Monboisse,et al.  Identification of CD47/integrin-associated protein and alpha(v)beta3 as two receptors for the alpha3(IV) chain of type IV collagen on tumor cells. , 1999, Cancer research.

[158]  T. Wilt,et al.  Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. , 1999, The New England journal of medicine.

[159]  J. Monboisse,et al.  A peptide of the alpha3 chain of type IV collagen protects basement membrane against damage by PMN. , 1999, Biochemical and biophysical research communications.

[160]  H. Kleinman,et al.  Identification of endothelial cell binding sites on the laminin γ1 chain , 1999 .

[161]  V. Sukhatme,et al.  Antiangiogenic activity of restin, NC10 domain of human collagen XV: comparison to endostatin. , 1999, Biochemical and biophysical research communications.

[162]  H. Kleinman,et al.  Identification of laminin α1 and β1 chain peptides active for endothelial cell adhesion, tube formation, and aortic sprouting , 1999 .

[163]  H. Kleinman,et al.  Identification of endothelial cell binding sites on the laminin gamma 1 chain. , 1999, Circulation research.

[164]  H. Kleinman,et al.  Identification of laminin alpha1 and beta1 chain peptides active for endothelial cell adhesion, tube formation, and aortic sprouting. , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[165]  M. Nugent,et al.  Antisense targeting of perlecan blocks tumor growth and angiogenesis in vivo. , 1998, The Journal of clinical investigation.

[166]  W. Graier,et al.  ORIGIN AND FUNCTION OF EPOXYEICOSATRIENOIC ACIDS IN VASCULAR ENDOTHELIAL CELLS: MORE THAN JUST ENDOTHELIUM‐DERIVED HYPERPOLARIZING FACTOR? , 1998, Clinical and experimental pharmacology & physiology.

[167]  R. DuBois,et al.  Cyclooxygenase Regulates Angiogenesis Induced by Colon Cancer Cells , 1998, Cell.

[168]  S. Narumiya,et al.  Patent ductus arteriosus and neonatal death in prostaglandin receptor EP4-deficient mice. , 1998, Biochemical and biophysical research communications.

[169]  William Arbuthnot Sir Lane,et al.  Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth , 1997, Cell.

[170]  K. Honn,et al.  Involvement of the multiple tumor suppressor genes and 12-lipoxygenase in human prostate cancer. Therapeutic implications. , 1997, Advances in experimental medicine and biology.

[171]  D. Hanahan,et al.  Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis , 1996, Cell.

[172]  D. Grignon,et al.  Elevated 12-lipoxygenase mRNA expression correlates with advanced stage and poor differentiation of human prostate cancer. , 1995, Urology.

[173]  R. Natarajan,et al.  A leukocyte type of 12-lipoxygenase is expressed in human vascular and mononuclear cells. Evidence for upregulation by angiotensin II. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[174]  K. Honn,et al.  12(S)-HETE is a mitogenic factor for microvascular endothelial cells: its potential role in angiogenesis. , 1995, Biochemical and biophysical research communications.

[175]  A. Yayon,et al.  Perlecan, basal lamina proteoglycan, promotes basic fibroblast growth factor-receptor binding, mitogenesis, and angiogenesis , 1994, Cell.

[176]  D. Cheresh,et al.  Requirement of vascular integrin alpha v beta 3 for angiogenesis. , 1994, Science.

[177]  R. Iozzo Perlecan: a gem of a proteoglycan. , 1994, Matrix biology : journal of the International Society for Matrix Biology.

[178]  J. Tímár,et al.  The lipoxygenase metabolite, 12(S)-HETE, induces a protein kinase C-dependent cytoskeletal rearrangement and retraction of microvascular endothelial cells. , 1993, Experimental cell research.

[179]  K. Honn,et al.  Protein kinase C-dependent effects of 12(S)-HETE on endothelial cell vitronectin receptor and fibronectin receptor , 1993, The Journal of cell biology.

[180]  M. Thun,et al.  Aspirin use and reduced risk of fatal colon cancer. , 1991, The New England journal of medicine.

[181]  J. Huttunen,et al.  Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. , 1987, The New England journal of medicine.

[182]  W. Waddell,et al.  Sulindac for polyposis of the colon , 1983, Journal of surgical oncology.